GlassScriptPhysician profile
Abhay Kunmar Suda
NPI 1962454967
$8,022.25
in general payments reported to CMS, 2019-2025
47 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,964 · 2021: $1,190 · 2022: $1,087 · 2023: $1,227 · 2024: $879 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,060.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $711.75 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Senseonics, Incorporated | $666.00 | 2019-2020 | |
| Mannkind Corporation | $564.97 | 2019-2024 | Afrezza |
| Amgen INC. | $529.19 | 2019-2024 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $472.28 | 2019-2023 | Farxiga |
| Abbott Laboratories | $454.30 | 2020-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $406.81 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $227.25 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.34 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $159.41 | 2020-2024 | Rotarix, Shingrix, Arexvy |
| Boston Scientific Corporation | $150.00 | 2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $147.22 | 2021-2024 | |
| Cranial Technologies, INC | $145.77 | 2019-2022 | |
| Medtronic, INC. | $144.41 | 2021-2023 | Inpen Smart Insulin Delivery System |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $139.55 | 2019-2020 | |
| Ibsa Pharma INC. | $137.62 | 2019-2024 | Tirosint, Licart, Licart |
| Esperion Therapeutics, INC. | $127.36 | 2020-2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $113.34 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $106.80 | 2020-2024 | Unithroid |
| Sanofi Pasteur INC. | $96.56 | 2019-2024 | |
| Medtronic Minimed, INC. | $94.41 | 2019-2020 | |
| Kaleo, INC. | $92.31 | 2019-2022 | |
| Dexcom, INC. | $91.22 | 2021-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $89.55 | 2022-2023 | |
| Amarin Pharma, INC. | $74.76 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $72.24 | 2020-2021 | |
| Genentech USA, INC. | $69.16 | 2019-2021 | |
| Cequr Corporation | $56.48 | 2022-2023 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $55.73 | 2019-2020 | |
| Becton, Dickinson and Company | $55.62 | 2020-2022 | |
| Corcept Therapeutics | $50.77 | 2019-2024 | Korlym |
| Tolmar, INC. | $46.33 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $44.81 | 2019-2021 | |
| Clarus Therapeutics INC. | $44.70 | 2021 | |
| Zealand Pharma US, INC. | $44.13 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $41.39 | 2021 | |
| Intuity Medical INC | $33.08 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Vistapharm, INC. | $29.66 | 2021 | |
| Althera Pharmaceuticals LLC | $26.17 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.24 | 2023 | |
| Beta Bionics, INC. | $21.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Valeritas, INC. | $21.48 | 2019 | |
| Ptc Therapeutics, INC. | $14.09 | 2021 | |
| Shire North American Group INC | $13.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.62 | 2019 | |
| Amryt Pharma Holdings LTD | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhay Suda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.